2018
DOI: 10.1016/j.jalz.2018.06.360
|View full text |Cite
|
Sign up to set email alerts
|

P1‐352: What Can the Mild Behavioral Impairment Checklist (Mbi‐c) Tell Us About Cognition and Behavior in Parkinson's Disease?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1
1

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Further, the MBI-C has demonstrated internal consistency, test-retest reliability (Mallo et al, 2018c), and discriminative validity from the NPI (Kang et al, 2018;Mallo et al, 2018c). In terms of imaging and biomarker validations, the MBI-C is associated with worsening cognition and temporal lobe atrophy in those with Parkinson's Disease (Monchi et al, 2018). Very recent data has correlated MBI-C score with PET ß-amyloid burden, in those with normal cognition, again supporting the utility of the MBI-C in case finding for early stage neurodegenerative disease in advance of overt cognitive impairment (Lussier et al, 2019).…”
Section: Introductionmentioning
confidence: 95%
“…Further, the MBI-C has demonstrated internal consistency, test-retest reliability (Mallo et al, 2018c), and discriminative validity from the NPI (Kang et al, 2018;Mallo et al, 2018c). In terms of imaging and biomarker validations, the MBI-C is associated with worsening cognition and temporal lobe atrophy in those with Parkinson's Disease (Monchi et al, 2018). Very recent data has correlated MBI-C score with PET ß-amyloid burden, in those with normal cognition, again supporting the utility of the MBI-C in case finding for early stage neurodegenerative disease in advance of overt cognitive impairment (Lussier et al, 2019).…”
Section: Introductionmentioning
confidence: 95%
“…Further, the MBI-C has demonstrated internal consistency, test-retest reliability (Mallo et al, 2018c), and discriminative validity from the NPI (Kang et al, 2018;Mallo et al, 2018c). In terms of imaging and biomarker validations, the MBI-C is associated with worsening cognition and temporal lobe atrophy in those with Parkinson's Disease (Monchi et al, 2018). Very recent data has correlated MBI-C score with PET ß-amyloid burden, in those with normal cognition, again supporting the utility of the MBI-C in case finding for early stage neurodegenerative disease in advance of overt cognitive impairment (Lussier et al, 2019).…”
Section: Introductionmentioning
confidence: 95%